Skip to content
Dx

ICD-10-CM 2027 diagnosis code

D75.AGlucose-6-phosphate dehydrogenase (G6PD) deficiency without anemia

✓ Billable / specific

D75.A is a valid, billable ICD-10-CM code for glucose-6-phosphate dehydrogenase (g6pd) deficiency without anemia. It can be reported on claims for dates of service from October 1, 2026 – September 30, 2027.Short description: Glucose-6-phosphate dehydrgnse (G6PD) defic without anemia

Code last changed in FY2020 (effective October 1, 2019). Source: official FY2027 ICD-10-CM release from CDC/NCHS and CMS. Page updated September 29, 2026. About our data

About D75.A

D75.A is the ICD-10-CM diagnosis code for glucose-6-phosphate dehydrogenase (G6PD) deficiency without anemia. It belongs to category D75 (other and unspecified diseases of blood and blood-forming organs), block D70-D77 (other disorders of blood and blood-forming organs) and chapter 3 (diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within D75, choose D75.A (Glucose-6-phosphate dehydrogenase (G6PD) deficiency without anemia) only when documentation doesn't support a more specific option: familial erythrocytosis (D75.0), secondary polycythemia (D75.1), other specified diseases of blood and blood-forming organs (D75.8) and disease of blood and blood-forming organs, unspecified (D75.9).

Don't report D75.A together with the conditions in its Excludes1 note: glucose-6-phosphate dehydrogenase (G6PD) deficiency with anemia (D55.0).

It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.

In MS-DRG v44.0, it is part of the grouping logic for DRG 814 (Reticuloendothelial and Immunity Disorders with MCC, relative weight 2.0729), DRG 815 (Reticuloendothelial and Immunity Disorders with CC, relative weight 1.0444) and DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC, relative weight 0.7381), in MDC 16 (Diseases and Disorders of the Blood and Blood Forming Organs and Immunological Disorders), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It was added in FY2020, effective October 1, 2019.

Coding notes

Excludes1Not coded here — never report together with this code
  • glucose-6-phosphate dehydrogenase (G6PD) deficiency with anemia (D55.0)

Notes that apply from higher levels

Instructions written at a parent level also apply to D75.A.

› From D75 Other and unspecified diseases of blood and blood-forming organs
Excludes2
  • acute lymphadenitis (L04.-)
  • chronic lymphadenitis (I88.1)
  • enlarged lymph nodes (R59.-)
  • hypergammaglobulinemia NOS (D89.2)
  • lymphadenitis NOS (I88.9)
  • mesenteric lymphadenitis (acute) (chronic) (I88.0)

Broader instructions also apply from Chapter 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism.

Alphabetic index entries

1 entries

Terms in the official ICD-10-CM index that lead to D75.A.

Codes whose notes reference D75.A

MS-DRG v44.0 grouping

All DRGs →

Inpatient MS-DRGs this diagnosis can group to, as the principal or a secondary diagnosis, depending on the rest of the claim.

Code history

  1. 2016
  2. 2017
  3. 2018
  4. 2019
  5. 2020
  6. 2021
  7. 2022
  8. 2023
  9. 2024
  10. 2025
  11. 2026
  12. 2027
  • FY2020 (effective 10/1/2019): Added
  • No changes since FY2020.

Common questions about D75.A

Is D75.A billable?

Yes. D75.A is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).

Can D75.A be used as a principal diagnosis?

Yes. The Medicare Code Editor doesn't restrict D75.A as a principal diagnosis.

Is D75.A a CC or MCC?

No. D75.A is neither a CC nor an MCC under MS-DRG v44.0.

What DRG does D75.A group to?

D75.A is used in the MS-DRG v44.0 logic for MS-DRG 814 (Reticuloendothelial and Immunity Disorders with MCC), MS-DRG 815 (Reticuloendothelial and Immunity Disorders with CC) and MS-DRG 816 (Reticuloendothelial and Immunity Disorders without CC/MCC). Which one applies depends on whether it is the principal diagnosis and on the rest of the claim.